We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSystem1 Group Regulatory News (SYS1)

Share Price Information for System1 Group (SYS1)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 490.00
Bid: 480.00
Ask: 500.00
Change: 0.00 (0.00%)
Spread: 20.00 (4.167%)
Open: 490.00
High: 490.00
Low: 490.00
Prev. Close: 490.00
SYS1 Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Results for the 12 months ended 31 December 2016

9 Feb 2017 07:00

RNS Number : 3914W
BrainJuicer Group PLC
09 February 2017
 

 

Press Release

9 February 2017

 

 

BrainJuicer Group PLC

("BrainJuicer" or "the Group" or "the Company")

 

Unaudited financial results for the twelve months ended 31 December 2016

 

BrainJuicer Group PLC (AIM: BJU), the international marketing and market research agency, today announces its results for the twelve months ended 31 December 2016.

 

Highlights

o

24% revenue growth to £31.24m (2015: £25.18m), 15% in constant currency

o

27% gross profit growth to £25.64m (2015: £20.25m), 15% in constant currency

o

38% increase in profit before tax to £6.20m (2015: £4.50m)

o

31% increase in profit after tax to £3.97m (2015: £3.03m)

o

33% increase in fully diluted earnings per share to 30.3p (2015: 22.7p)

o

Cash inflow before financing of £6.34m (160% of profit after tax)

o

£7.75m cash at year-end (31 December 2015: £6.37m) and no debt

o

£5.25m returned to shareholders by way of dividends and share buy-backs during year

 

Commenting on the Company's results, John Kearon, Founder and Chief Executive Officer of BrainJuicer, said: "Our double-digit growth is testament to the strength of our pioneering System 1 research methods and the hard work of a fantastic team. We were delighted with the successful launch of our Advertising agency, 'System1' and are looking forward to further growth in our core-four research products in the year to come."

 

The Company can be found at www.brainjuicer.com.

 

The information contained within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014. Upon the publication of this announcement, this inside information is now considered to be in the public domain.

 

For further information, please contact:

BrainJuicer Group PLC

+44 20 7043 1000

John Kearon, Chief Executive Officer

James Geddes, Chief Financial Officer

investorrelations@brainjuicer.com

Canaccord Genuity Limited

+44 20 7523 8000

Simon Bridges

Emma Gabriel

 

 

 

 

 

 

 

 

BrainJuicer Group PLC

Financial information for the twelve months ended 31 December 2016

 

 

BUSINESS REVIEW

 

The Group's strong performance in the first half of 2016 continued over the second six months. For the 12 months as a whole, revenue grew 24% (15% in constant currency) and gross profit, our main top line indicator, by 27% (15% in constant currency). In spite of continued investment in new services, particularly investment in setting up our Advertising Agency business, overheads grew by less than revenue. Margins improved accordingly, and profit before tax increased by 38%. Cash flow was again strong, and we finished the period with cash of £7.75m at 31 December 2016 and no debt (31 December 2015: £6.37m and no debt) after having returned £5.25m to shareholders by way of dividends and share buy-backs.

 

This return to double digit revenue growth followed a two-year period of flat revenues while our Juice Generation qualitative business and Behavioural Consultancy services were being de-emphasised. These services are no longer material to the Group and revenue is now predominantly generated by our faster growing core quantitative products.

 

Ad Testing and Brand Tracking performed particularly well, with gross profit increasing by 81%. These products represented 39% of our business over the year, and much of this business is ongoing in nature (as opposed to ad hoc). These products have delivered strong growth over a number of years now, with 40% compound annual growth in gross profit over the last five years (using 2011 as the base). We introduced a new framework for successful brand-building last year ("Fame, Feeling & Fluency"), and this has helped propel the growth.

 

Gross profit from our innovation services (Predictive Markets and Concept Testing) grew by 18%. Predictive Markets, our largest single product (32% of our business in 2016) grew 12%. This was achieved despite pricing pressure, which we have been addressing with a lower cost and cheaper-to-deliver "express" version of the product. We have also developed a "Fluent Innovation" framework to better express the value of Predictive Markets in guiding innovation.

 

In terms of geography, gross profit in the US business grew 40% (22% in constant currency), and that after several years of double digit growth. The US is now our largest market by a significant margin, making up 42% of our total gross profit in 2016. In Continental Europe we grew gross profit by 64% (44% in constant currency), rebounding strongly after a decline in 2015. Our Brazilian business grew gross profit by 12% (4% in constant currency). This is a relatively small part of our business but nevertheless an important one, working closely with our US Miami office in serving clients across the LATAM region. In the UK, our second largest market, gross profit declined by 7% due to sharp declines in two large clients for specific reasons associated with those two clients. In one of these, for example, a large multi-year programme of work had come to a natural end. The UK business supports our smaller offices, and in 2016, provided the resources for our entry into the Australian market where we have made an encouraging start. Gross profit in our Singapore and China region grew 16% (3% in constant currency). We have shut down our small Indian operation due to lack of scale, the small project sizes inherent in that market, and the bigger opportunities identified in our other markets.

 

In early 2016 we launched our new creative Advertising Agency, System1, and have invested £0.31m to date in the form of operating losses, in line with what we had planned. Potential clients have given positive feedback, and we remain hopeful that this will generate a new business stream for us over the long term, and further strengthen our Ad Testing and Brand Tracking market research services.

 

BrainJuicer Group PLC

Financial information for the twelve months ended 31 December 2016

 

 

BUSINESS REVIEW

 

Underlying overheads (i.e. overheads before bonus, System1 Advertising Agency start-up costs, other one-off costs, and share-based payments) grew 6%, and total overheads grew 24%.

 

2016

2015

growth

Underlying overheads

£16.05m

£15.12m

6%

Bonus

£2.40m

£0.06

System1 Advertising Agency overheads

£0.41m

-

Share-based payments

£0.55m

£0.20m

One-off costs (due diligence and office move costs in 2015)

-

£0.32m

Total overheads

£19.41m

£15.70m

24%

 

The biggest cause of the increase in total overheads was our employee bonus which increased from a negligible amount last year to £2.40m this year. Bonuses for 2016 range from a maximum of 20% of salary for most of our employees up to a maximum of 50% of salary for the management team. The main determinant of bonuses is the Company's operating profit, and for this reason we have started labelling bonuses "Profit Share" internally, and shall start to do-so externally also.

 

System1 Advertising Agency overheads were £0.41m. This new business generated £0.10m of gross profit, leaving the £0.31m operating loss, mentioned above. Share based payments increased from £0.20m in 2015 to £0.55m in 2016 due to anticipated vesting of the current Executive Director LTIP. There were no other particularly large or unusual costs this year.

 

Our effective tax rate increased from 33% to 36% due to the higher proportion of profit from the US and Continental Europe where corporation tax rates are higher than the UK. This dampened growth of profit after tax to 31%. The Company repurchased 646,306 shares (plus a further 245,818 of option shares) during the year, and this has helped our earnings per share. Diluted earnings per share grew 33% to 30.3p per share.

 

Cash flow continues to be strong, with operating cash flow (before financing) of £6.34m, up from £2.70m in 2015. As always, cash conversion was strong, and particularly so this year due to the negligible bonus relating to 2015 (and paid in 2016).

 

The Company paid dividends of £2.05m and repurchased £3.20m of shares and option shares (net of exercise price) in the year, and intends to continue to return surplus cash to shareholders via a mix of dividends and share buy backs, depending on our share price. In addition to nearly £8m of cash and no debt, the Company has a £2m unused, committed bank facility.

 

As previously announced we are changing our year end from 31 December to 31 March. We shall report our audited results for the 15 months to 31 March 2017 during June 2017. At this time we shall also announce a proposed final dividend payment.

 

 

 

 

 

BrainJuicer Group PLC

Financial information for the twelve months ended 31 December 2016

 

 

BUSINESS REVIEW

 

Outlook

We had six macro objectives for 2016: continue the momentum in the US business; grow in our other regions as we have done in the US; grow gross profit by more than headcount; major on core products (and continue to de-emphasise non-core services); set up System1 Advertising Agency; experiment with Zappistore (which is a low cost "do-it-yourself" means for clients to buy our products via the Zappistore website). Apart from our experiment with Zappistore, which is still in its infancy, we are pleased with performance against each of the other objectives.

 

Our objectives over the next financial year are similar. In particular, we are looking to roll out the business development processes which we have implemented successfully in the US, across our other regions, particularly the UK. In that regard, we have promoted the head of our Americas business, Alex Hunt, to lead our market research account management function globally. To reflect the importance of this position, we will be appointing him to our board of directors with effect from 1st April 2017.

 

We will continue to focus on our core products, particularly Ad Testing and Brand Tracking where we are beginning to get a foothold in large clients. These products are comparatively easy to grow and scale, and they also provide more revenue visibility than our other products. Nevertheless, our business still remains predominantly ad hoc, with limited revenue visibility, and as always we need to acknowledge that we cannot predict with very much certainty how revenue growth will unfold over the coming financial year. Having said that, we are pleased with the continued progress across the business and remain confident in its long-term potential.

 

As we think about the longer term, we are planning on a re-branding of the business to present a unified theme across our market research and advertising agency businesses and to reflect our behavioural science prominence. We view this as the start of a new chapter in the life of the Company, as we seek to guide clients more pro-actively towards profitable marketing and building their brands.

 

 

John Kearon James Geddes

Chief Executive Officer Chief Financial Officer

 

 

 

 

 

BrainJuicer Group PLC

Financial information for the twelve months ended 31 December 2016

 

5 YEAR SUMMARY

(£000s unless specified otherwise)

 

 

Year to 31 December

2016

2015

2014

2013

2012

Revenue

31,236

25,184

24,645

24,457

20,822

growth

24%

2%

1%

17%

-

Gross profit

25,643

20,250

19,410

19,087

16,068

growth

27%

4%

2%

19%

-

Operating profit

6,229

4,546

4,301

3,550

1,513

growth

37%

6%

21%

135%

-45%

Pre-tax profit

6,200

4,501

4,286

3,556

1,515

growth

38%

5%

21%

135%

-45%

Post-tax profit

3,968

3,032

2,897

2,435

1,038

growth

31%

5%

19%

135%

-44%

EPS - diluted

30.3p

22.7p

21.3p

18.7p

7.9p

growth

33%

7%

14%

137%

-44%

Cash flow pre financing

6,337

2,696

3,157

4,466

866

Cash balance (no debt)

7,754

6,365

5,347

6,188

3,755

Dividend per share (interim and final)

4.6p

4.5p

4.3p

3.9p

3.1p

growth

2%

5%

10%

26%

3%

Special dividend per share

12.0p

-

12.0p

12.0p

-

Share buy-backs (net of stock option proceeds)*

3,195

948

1,938

71

408

Number of clients

223

243

235

224

217

growth

-8%

3%

5%

3%

9%

Average headcount

157

158

152

138

148

growth

-1%

4%

10%

-7%

19%

 

*2014 includes £1,239,000 for the cash-settling of part of the Company's long-term incentive plan

 

 

CONDENSED CONSOLIDATED INCOME STATEMENT

for the six months ended 31 December 2016

 

 

Note

Six months ended 31 Dec

Year ended 31 Dec

2016

Unaudited

2015

Unaudited

2016

Unaudited

2015

Audited

£'000

£'000

£'000

£'000

Revenue

4

18,193

13,574

31,236

25,184

Cost of sales

(3,235)

(2,578)

(5,593)

(4,934)

Gross profit

4

14,958

10,996

25,643

20,250

Administrative expenses

(10,396)

(7,624)

(19,414)

(15,704)

Operating profit

4

4,562

3,372

6,229

4,546

Finance costs

(12)

(10)

(29)

(45)

Profit before taxation

4

4,550

3,362

6,200

4,501

Income tax expense

(1,636)

(1,093)

(2,232)

(1,469)

Profit for the financial period

2,914

2,269

3,968

3,032

Attributable to the equity holders of the Company

2,914

2,269

3,968

3,032

 

 

Earnings per share attributable to equity

holders of the Company

 

Basic earnings per share

5

23.7p

17.9p

31.9p

23.9p

Diluted earnings per share

5

22.4p

17.1p

30.3p

22.7p

 

All of the activities of the Group are classed as continuing.

 

 

 

CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

for the six months ended 31 December 2016

 

 

 

 

 

 

 

Six months ended 31 Dec

Year ended 31 Dec

2016

Unaudited

2015

Unaudited

2016

Unaudited

2015

Audited

£'000

£'000

£'000

£'000

Profit for the financial period

2,920

2,269

3,968

3,032

Other comprehensive income:

Items that may be subsequently reclassified to profit or loss

Exchange differences on translating foreign operations

158

20

565

(88)

Other comprehensive income for the period, net of tax

158

20

565

(88)

Total comprehensive income for the period attributable to equity holders

3,078

2,289

4,533

2,944

 

 

 

CONDENSED CONSOLIDATED BALANCE SHEET

as at 31 December 2016

 

 

Note

As at 31 Dec

2016

Unaudited

2015

Audited

£'000

£'000

ASSETS

Non-current assets

Property, plant and equipment

309

304

Intangible assets

251

519

Deferred tax asset

730

589

1,290

1,412

Current assets

Inventories

137

90

Trade and other receivables

9,316

6,595

Cash and cash equivalents

7,754

6,365

17,207

13,050

Total assets

18,497

14,462

EQUITY

Capital and reserves attributable to equity holders of the Company

Share capital

8

132

132

Share premium account

1,601

1,599

Merger reserve

477

477

Foreign currency translation reserve

413

(152)

Retained earnings

6,639

7,184

Total equity

9,262

9,240

LIABILITIES

Non-current liabilities

Provisions

490

469

490

469

Current liabilities

Provisions

260

263

Trade and other payables

8,095

4,161

Current income tax liabilities

390

329

8,745

4,753

Total liabilities

9,235

5,222

Total equity and liabilities

18,497

14,462

 

 

 

 

CONDENSED CONSOLIDATED CASH FLOW STATEMENT

for the year ended 31 December 2016

 

 

Note

Year ended 31 Dec

2016

Unaudited

2015

Audited

£'000

£'000

Net cash generated from operations

7

8,358

4,137

Tax paid

(1,845)

(1,119)

Net cash generated from operating activities

6,513

3,018

Cash flows from investing activities

Purchases of property, plant and equipment

(165)

(291)

Purchase of intangible assets

(11)

(31)

Net cash used by investing activities

(176)

(322)

Net cash flow before financing activities

6,337

2,696

Cash flows from financing activities

Interest

(29)

(45)

Issue of shares

2

20

Proceeds from sale of treasury shares

339

211

Purchase of own shares

(3,536)

(1,159)

Dividends paid to owners

(2,052)

(544)

Net cash used by financing activities

(5,276)

(1,517)

Net increase in cash and cash equivalents

1,061

1,179

Cash and cash equivalents at beginning of year

6,365

5,347

Exchange gains/(losses) on cash and cash equivalents

328

(161)

Cash and cash equivalents at end of year

7,754

6,365

 

 

 

 

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

for the year ended 31 December 2016

 

 

 

 

 

Note

Sharecapital

 

Share premium account

 

Mergerreserve

 

Foreign currency translation reserve

 

Retained earnings

 

Total

 

£'000

£'000

£'000

£'000

£'000

£'000

At 1 January 2015

131

1,580

477

(64)

5,581

7,705

Profit for the financial year

-

-

-

-

3,032

3,032

Other comprehensive income:

- currency translation differences

-

-

-

(88)

-

(88)

Total comprehensive income

-

-

-

(88)

3,032

2,944

Transactions with owners:

Employee share options scheme:

- exercise of share options

1

19

-

-

-

20

- value of employee services

-

-

-

-

112

112

- current tax credited to equity

-

-

-

-

169

169

- deferred tax debited to equity

-

-

-

-

(218)

(218)

Dividends paid to owners

-

-

-

-

(544)

(544)

Sale of treasury shares

-

-

-

-

211

211

Purchase of own shares

-

-

-

-

(1,159)

(1,159)

1

19

-

-

(1,429)

(1,409)

At 31 December 2015

132

1,599

477

(152)

7,184

9,240

Profit for the financial year

-

-

-

-

3,968

3,968

Other comprehensive income:

- currency translation differences

-

-

-

565

-

565

Total comprehensive income

-

-

-

565

3,968

4,533

Transactions with owners:

Employee share options scheme:

- exercise of share options

8

-

2

-

-

-

2

- value of employee services

-

-

-

-

270

270

- current tax credited to equity

-

-

-

-

207

207

- deferred tax credited to equity

-

-

-

-

259

259

Dividends paid to owners

6

-

-

-

-

(2,052)

(2,052)

Sale of treasury shares

8

-

-

-

-

339

339

Purchase of own shares

8

-

-

-

-

(3,536)

(3,536)

-

2

-

-

(4,513)

(4,511)

At 31 December 2016

132

1,601

477

413

6,639

9,262

 

 

 

BrainJuicer Group PLC

Financial information for the twelve months ended 31 December 2016

 

 

1. General information

 

BrainJuicer Group PLC ("the Company") is United Kingdom resident, and its subsidiaries (together "the Group") provide marketing and market research consultancy services. The Company's shares are listed on the Alternative Investment Market of the London Stock Exchange ("AIM"). The address of the Company's registered office is Russell Square House, 10-12 Russell Square, London WC1B 5EH.

 

The Board of Directors approved this condensed consolidated interim financial information for issue on 9 February 2017.

 

The financial information set out in this interim report does not constitute statutory accounts as defined in Section 434 of the Companies Act 2006 and is unaudited. The Group's latest statutory financial statements were for the year ended 31 December 2015 and these have been filed with the Registrar of Companies. The auditor's report on those financial statements was unqualified and did not contain any statement under Section 498 of the Companies Act 2006.

 

2. Basis of Preparation

 

This condensed consolidated interim financial information has been prepared in accordance with IAS 34, 'Interim Financial Reporting' as adopted by the European Union. This financial information should be read in conjunction with the annual financial statements for the year ended 31 December 2015, which have been prepared in accordance with IFRSs as adopted by the European Union.

 

3. Principal accounting policies

 

The principal accounting policies adopted are consistent with those of the annual financial statements for the year ended 31 December 2015, as described in those annual financial statements.

 

4. Segment information

 

Management review the following key segmental information: gross profit and operating profit before allocation of central overheads of the Group's geographic operating units ("Reportable Segments"); and the split of business by type of research solution.

 

 

4. Segment information (continued)

Financial performance of

Reportable Segments:

Year ended 31 Dec 2016

Year ended 31 Dec 2015

Revenue

Gross profit

Operating profit

Revenue

Gross

profit

Operating Profit

£'000

£'000

£'000

£'000

£'000

£'000

Research Business

US

12,484

10,894

6,294

9,273

7,758

4,419

United Kingdom

7,872

6,229

3,684

8,445

6,733

4,527

Continental Europe

6,561

5,131

3,071

4,088

3,125

1,623

Asia

1,925

1,496

721

1,884

1,489

563

Brazil

1,562

1,277

629

1,494

1,145

622

Australia

579

507

324

-

-

-

30,983

25,534

14,723

25,184

20,250

11,754

Advertising Agency Business

United Kingdom

253

109

(306)

-

-

-

31,236

25,643

14,417

25,184

20,250

11,754

 

 

Revenue and gross profit

by research solution:

Year ended 31 Dec 2016

Year ended 31 Dec 2015

Revenue

Gross Profit

Revenue

Gross Profit

£'000

£'000

£'000

£'000

Research Business

Ad Testing

8,213

7,162

5,034

4,313

Brand Tracking

3,745

2,766

1,732

1,186

Communications products

11,958

9,928

6,766

5,499

Predictive Markets

9,286

8,229

8,396

7,339

Concept Testing

3,971

3,283

3,034

2,454

Innovation products

13,257

11,512

11,430

9,793

Total core products

25,215

21,440

18,196

15,292

Other services

5,768

4,094

6,988

4,958

30,983

25,534

25,184

20,250

Advertising Agency Business

253

109

-

-

31,236

25,643

25,184

20,250

 

Segmental revenue is revenue generated from external customers and so excludes intercompany revenue and is attributable to geographical areas based upon the location in which the service is delivered.

 

Segmental operating profit excludes costs relating to central services provided by our Operations, IT, Marketing, HR and Finance teams and our Board of Directors.

BrainJuicer Group PLC

Financial information for the twelve months ended 31 December 2016

 

 

4. Segment information (continued)

 

A reconciliation of total operating profit for Reportable Segments to total profit before income tax is set out below:

 

Year ended 31 Dec

2016

2015

£'000

£'000

Operating profit for reportable segments

14,417

11,754

Central overheads

(8,188)

(7,208)

Operating profit

6,229

4,546

Finance costs

(29)

(45)

Profit before income tax

6,200

4,501

 

5. Earnings per share

 

(a) Basic earnings per share

Basic earnings per share is calculated by dividing the profit attributable to equity holders of the Company by the weighted average number of Ordinary Shares in issue during the year.

 

Year ended 31 Dec

2016

2015

Profit attributable to equity holders of the Company (£'000)

3,968

3,032

Weighted average number of Ordinary Shares in issue

12,426,582

12,684,787

Basic earnings per share

31.9p

23.9p

 

(b) Diluted earnings per share

Diluted earnings per share is calculated by adjusting the weighted average number of shares outstanding assuming conversion of all dilutive share options to Ordinary Shares.

 

Year ended 31 Dec

2016

2015

Profit attributable to equity holders of the Company and profit used to determine diluted earnings per share (£'000)

3,968

3,032

Weighted average number of Ordinary Shares in issue

12,426,582

12,684,787

Share options

681,439

642,941

Weighted average number of Ordinary Shares for diluted earnings per share

13,108,021

13,327,728

Diluted earnings per share

30.3p

22.7p

 

 

6. Dividends

 

On 11 May 2016 the Company paid a final dividend of 3.5 pence per share, amounting to £445,000 in respect of the year ended 31 December 2015. On 20 October 2016, the Company paid an interim dividend of 1.1 pence per share, amounting to £135,000, in respect of the year ended 31 December 2016 and a special dividend of 12 pence per share amounting to £1,472,000.

 

7. Net cash generated from operations

 

Year ended 31 Dec

2016

2015

£'000

£'000

Profit before taxation

6,200

4,501

Depreciation

167

150

Amortisation

279

309

Interest paid

29

45

Share-based payment expense

270

112

(increase)/decrease in inventory

(47)

105

(Increase)/decrease in receivables

(2,721)

129

Increase/(decrease) in payables

3,951

(1,287)

Exchange differences on operating items

230

73

Net cash generated from operations

8,358

4,137

 

8. Share capital

 

During the year the Company issued 3,011 Ordinary Shares ("shares") on the exercise of employee share options for cash consideration of £1,875 of which £1,845 was credited to share premium and £30 to share capital. The Company transferred 391,896 shares out of treasury to satisfy the exercise of employee share options at a weighted average exercise price of 86.5 pence per share for total consideration of £339,000. The weighted average share price at exercise date was 430.8 pence per share. During the year the Company repurchased 892,124 shares at a weighted average price of 394.9 pence per share. The total consideration payable on repurchase, including commission, amounted to £3,536,000.

 

At 31 December 2016, the Company had 13,226,773 shares in issue (31 Dec 2015: 13,223,762) of which 1,009,496 were held in treasury (31 Dec 2015: 509,268) and the Company had 967,177 share options outstanding of which 376,057 were fully vested at the end of the year.

 

9. Related party transactions

 

Dividends paid to directors during the year were as follows:

 

Year ended 31 Dec

2016

2015

£

£

John Kearon

575,259

165,980

James Geddes

30,736

6,808

Alex Batchelor

21,204

4,380

Ken Ford

3,320

860

Robert Brand

4,980

1,290

Graham Blashill

830

215

636,329

179,533

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
FR VVLFBDLFXBBD
Date   Source Headline
16th Apr 20247:00 amRNSTrading Update
24th Jan 20247:00 amRNSTrading Update
12th Dec 202312:51 pmRNSPresentation via Investor Meet Company
6th Dec 20237:00 amRNSChange of Auditor
6th Dec 20237:00 amRNSInterim Results
24th Oct 20237:00 amRNSTrading Update
27th Sep 20236:00 pmRNSResult of AGM
27th Sep 20237:00 amRNSTrading Update
31st Aug 20237:00 amRNSAnnual Report and Notice of AGM
1st Aug 20237:00 amRNSPRELIMINARY RESULTS FOR THE YEAR ENDED 31 MAR 2023
31st Jul 20232:00 pmRNSPreliminary Results Presentation
13th Jul 20237:30 amRNSTrading update
30th Jun 20239:00 amRNSResolution of Complaint for Trademark Infringement
28th Jun 202311:00 amRNSHolding(s) in Company
3rd May 20233:15 pmRNSFurther re Result of General Meeting
21st Apr 202311:56 amRNSResult of General Meeting
13th Apr 20237:00 amRNSFurther re Requisitioned General Meeting
12th Apr 20237:00 amRNSTrading Update
5th Apr 202310:45 amRNSNotice of Trading Update
24th Mar 20234:00 pmRNSPosting of Circular and Notice of Requisitioned GM
24th Mar 20237:00 amRNSPosting of Circular and Notice of Requisitioned GM
7th Mar 20237:30 amRNSReceipt of Requisition Notice
28th Feb 202312:50 pmRNSCapital Markets Day
23rd Feb 20237:00 amRNSTrading Update
14th Feb 20237:00 amRNSCapital Markets Day
13th Jan 20232:00 pmRNSDirector/PDMR Shareholding
10th Jan 202310:30 amRNSDirector/PDMR Shareholding
10th Jan 20237:00 amRNSDirector/PDMR Shareholding
14th Dec 20224:00 pmRNSDirector/PDMR Shareholding
13th Dec 20226:25 pmRNSDirector/PDMR Shareholding
6th Dec 20224:15 pmRNSDirectorate Change
30th Nov 20227:00 amRNSInterim Results
25th Oct 20227:00 amRNSTrading Update
28th Sep 20226:15 pmRNSResult of AGM
31st Aug 202211:00 amRNSNotice of AGM
31st Aug 20227:00 amRNSDirectorate Change
31st Aug 20227:00 amRNSReview of strategic options
30th Aug 20226:00 pmRNSTransaction in Own Shares
19th Aug 20228:55 amRNSTransaction in Own Shares
3rd Aug 20225:45 pmRNSTransaction in Own Shares
2nd Aug 20223:45 pmRNSTransaction in Own Shares
29th Jul 20229:30 amRNSTransaction in Own Shares
26th Jul 20226:24 pmRNSTransaction in Own Shares
19th Jul 20224:00 pmRNSHolding(s) in Company
19th Jul 20223:00 pmRNSTransaction in Own Shares
18th Jul 20224:30 pmRNSTransaction in Own Shares
15th Jul 20225:15 pmRNSTransaction in Own Shares
12th Jul 20227:00 amRNSShare Buyback Programme
12th Jul 20227:00 amRNSPRELIMINARY RESULTS FOR THE YEAR ENDED 31 MAR 2022
12th Jul 20227:00 amRNSQuarterly Trading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.